Previous 10 | Next 10 |
FMC Corporation (FMC) is expected to report $0.45 for Q3 2023 NCS Multistage Holdings Inc. (NCSM) is expected to report $2.59 for Q3 2023 Third Century Bancorp (TDCB) is expected to report for Q3 2023 ZoomInfo Technologies Inc. (ZI) is expected to report $0.15 for Q3 2023 Matson I...
Pulmonx Corporation (LUNG) is expected to report $-0.45 for Q3 2023
REDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2023 after the close of trading ...
2023-10-10 16:41:31 ET More on Pulmonx Pulmonx Corporation (LUNG) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Pulmonx Historical earnings data for Pulmonx Financial information for Pulmonx For further details see: Pulmo...
Derrick Sung steps down from his position as Chief Financial Officer to pursue another opportunity; John McKune appointed Interim Chief Financial Officer Preliminary, unaudited third quarter 2023 revenue expected to be approximately $17.6 million Management to host conference call on Octo...
2023-09-25 17:15:50 ET Gainers: Pliant Therapeutics ( NASDAQ: PLRX ) +8% . ARS Pharmaceuticals ( SPRY ) +6% . Amylyx Pharmaceuticals ( AMLX ) +4% . Seres Therapeutics ( MCRB ) +2% . Pulmonx Corporation ( LUNG ) +2% . Lo...
2023-09-20 11:55:57 ET More on Health Care Sector: Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth consecutiv...
2023-08-06 02:20:58 ET Pulmonx Corporation (LUNG) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Dorothy Morgan - Investor Relations, Gilmartin Group LLC Glendon French - President and Chief Executive Officer Derrick Sung - Chief ...
2023-08-02 17:17:03 ET Pulmonx press release ( NASDAQ: LUNG ): Q2 GAAP EPS of -$0.43 beats by $0.02 . Revenue of $17.2M (+22.9% Y/Y) beats by $1.34M . For further details see: Pulmonx GAAP EPS of -$0.43 beats by $0.02, revenue of $17.2M beats by $1.34M
REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2023 ended June 30, 2023. Re...
News, Short Squeeze, Breakout and More Instantly...
2024-06-23 01:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Allarity Therapeutics Inc. (ALLR) rose 97.8% to $2.71 on volume of 44,141,232 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 1.1% to $0.0456 on volume of 28,670,184 shares Emergent Biosolutions Inc. (EBS) rose 67.7% to $3...
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the quarter ended March 31, 2024. Rec...